Company Information

  

Address: VALLONGATAN 1  
City: UPPSALA 
State:  
Zip Code: 752 28 
Telephone: 011 46 18 50 54 40 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Oasmia Pharmaceutical AB is a pharmaceutical company which develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatic which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The Company's shares are listed at NASDAQ Stockholm, NASDAQ Capital Markets and the Frankfurt Stock Exchange. We are a Swedish public company. Our principal executive offices are located in Uppsala, Sweden.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
There's no share overview data.

Key Financial Ratios and Statistics

FYE: 04/30

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.15Total Liab/Total Assets0.42
Net Inc/Total Assets-0.31Total Liab/Inv Cap1.68
Net Inc/Inv Cap-1.22Total Liab/Comm Equity0.20
Pretax Inc/Net Sales-952.47Interest Coverage Ratio-7.08
Net Inc/Net Sales-952.47Curr Debt/Equity0.56
Cash Flow/Net Sales-790.58LTD/EquityNA
SG&A/NetSales791.47Total Debt/Equity0.56
Asset Utilization   Liquidity  
Net Receivables Turnover0.04Quick Ratio0.16
Inventory Turnover0.19Current Ratio0.23
Inventory Day Sales0.00Net Rec/Curr Assets0.03
Net Sales/Work Cap0.00Inv/Curr Assets0.27
Net Sales/PP&E0.01  

Income Statement (Millions)

  4/30/2017 4/30/2016 4/30/2015 10/31/2014
Total Revenues(Net Sales) 0.02 0.79 0.25 0.21
Cost of Goods Sold 0.34 0.59 1.21 0.75
Selling & Admin Exps 15.04 16.15 11.38 6.49
Operating Income -15.87 -16.54 -12.96 -7.36
Interest Exp 2.24 1.20 1.14 0.71
Pretax Income -18.10 -17.64 -14.07 -8.07
Other Income 0.01 0.10 0.03 0.00
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -18.10 -17.64 -14.07 -8.07

Balance Sheet (Millions)

Assets 4/30/2017 4/30/2016 4/30/2015 10/31/2014
Cash & Short Term Investments 3.16 5.76 9.22 3.67
Receivables - Total 0.16 0.85 0.32 0.58
Inventories - Total 1.55 2.07 0.64 0.37
Total Current Assets 5.66 9.05 10.38 4.83
Net Property, Plant & Equipment 2.07 2.64 2.74 3.28
Total Assets 58.90 64.27 61.62 61.95
Liabilities        
Accounts Payable 5.32 5.92 3.60 3.44
Debt in Current Liabilities 19.05 17.44 12.81 19.59
Total Current Liabilities 24.98 23.63 16.63 25.47
Long-Term Debt NA NA NA NA
Total Liabilities 24.98 23.63 16.63 25.59
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 1.34 1.34 1.17 1.19
Retained Earnings -88.86 -78.11 -58.09 -57.74
Treasury Stock NA NA NA NA
Total Stockholders' Equity 33.92 40.64 44.99 36.36
Total Liabilities and Stockholders' Equity 58.90 64.27 61.62 61.95

Cash Flow Summary (Millions)

Categories 4/30/2017 4/30/2016 4/30/2015 10/31/2014
Net Cash Provided by Operating Activities -15.02 -15.97 -12.89 -7.53
Net Cash Provided by Investing Activities 1.36 1.26 -8.35 -1.65
Net Cash Provided by Financing Activities 13.86 14.64 18.68 6.33

Annual Summary Data (Millions)

Year Sales Net Income EPS
04/20140.01-16.13--
04/20150.25-14.07--
04/20160.79-17.64--
04/20170.02-18.10--
Growth Rates28.28----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1742930.50




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.